Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 10 (1) , 305-316
Abstract
A chimeric Eilat/ Chikungunya virus (EILV/CHIKV) was previously reported to replicate only in mosquito cells but capable of inducing robust adaptive immunity in animals. Here, we initially selected C7/10 cells to optimize the production of the chimeric virus. A two-step procedure produced highly purified virus stocks, which was shown to not cause hypersensitive reactions in a mouse sensitization study. We further optimized the dose and characterized the kinetics of EILV/CHIKV-induced immunity. A single dose of 108 PFU was sufficient for induction of high levels of CHIKV-specific IgM and IgG antibodies, memory B cell and CD8+ T cell responses. Compared to the live-attenuated CHIKV vaccine 181/25, EILV/CHIKV induced similar levels of CHIKV-specific memory B cells, but higher CD8+ T cell responses at day 28. It also induced stronger CD8+, but lower CD4+ T cell responses than another live-attenuated CHIKV strain (CHIKV/IRES) at day 55 post-vaccination. Lastly, the purified EILV/CHIKV triggered antiviral cytokine responses and activation of antigen presenting cell (APC)s in vivo, but did not induce APCs alone upon in vitro exposure. Overall, our results demonstrate that the EILV/CHIKV vaccine candidate is safe, inexpensive to produce and a potent inducer of both innate and adaptive immunity in mice.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI127744,R01AI153433)
This publication has 47 references indexed in Scilit:
- Eilat virus, a unique alphavirus with host range restricted to insects by RNA replicationProceedings of the National Academy of Sciences, 2012
- Attenuation of Chikungunya Virus Vaccine Strain 181/Clone 25 Is Determined by Two Amino Acid Substitutions in the E2 Envelope GlycoproteinJournal of Virology, 2012
- Chimeric Chikungunya Viruses Are Nonpathogenic in Highly Sensitive Mouse Models but Efficiently Induce a Protective Immune ResponseJournal of Virology, 2011
- Vγ4+T cells regulate host immune response to West Nile virus infectionFEMS Immunology & Medical Microbiology, 2011
- Design of Chimeric Alphaviruses with a Programmed, Attenuated, Cell Type-Restricted PhenotypeJournal of Virology, 2011
- A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infectionNature Medicine, 2010
- IL‐17‐producing γδ T cellsEuropean Journal of Immunology, 2009
- Chimeric alphavirus vaccine candidates for chikungunyaVaccine, 2008
- Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virusVaccine, 2008
- γδ T cells: an important source of IL-17Current Opinion in Immunology, 2008